Search

Background and Aim: The efficacy and safety of the recently introduced low‐volume purgatives in elderly people are not well known. Therefore, in this trial, we aimed to evaluate and compare the efficacy of two low‐volume agents, oral sulfate solution (OSS) and 2‐L polyethylene glycol with ascorbic acid (PEG‐Asc), in elderly people. Methods: A prospective, randomized, single‐blinded, multicenter, non‐inferiority trial was performed at three university‐affiliated hospitals in South Korea. Outpatients aged 65–80 years, who underwent elective colonoscopy, were enrolled. The primary outcome was the rate of adequate bowel preparation assessed using the Boston Bowel Preparation Scale. Results: A total of 199 subjects were randomized into the OSS (n = 99) or the 2‐L PEG‐Asc (n = 100) group. Of them, 189 subjects were included in the analysis of the primary outcome (OSS group 95 vs PEG‐Asc group 94). The proportion of adequate bowel preparation was 89.5% (85/95) in the OSS group and 93.6% (88/94) in the 2‐L PEG‐Asc group. OSS was not inferior to 2‐L PEG‐Asc according to the prespecified non‐inferiority margin of −15% (95% confidence interval for the difference, −12.1 to 3.8). Vomiting (11.6% vs 2.1%) and thirst (24.2% vs 11.7%) were more common in the OSS group than in the 2‐L PEG‐Asc group. Conclusions: OSS is an effective low‐volume purgative that is non‐inferior to 2‐L PEG‐Asc in elderly people. Both the low‐volume agents were identified to be well tolerated and safe in the healthy elderly population. [ABSTRACT FROM AUTHOR]

Background and Aim: PBK‐1701TC is a novel sulfate tablet‐based that contains 320 mg of simethicone and delivers 90% of the salt and water delivered by oral sulfate solution (OSS) preparation. This study evaluated the efficacy, safety, and tolerability of PBK‐1701TC compared with OSS in bowel preparation for colonoscopy. Methods: This randomized, multicenter, phase 3 non‐inferiority trial included adults aged 19 years or older with a body mass index of 19–30 kg/m2 undergoing colonoscopy at five university hospitals in Korea. The primary efficacy endpoint was successful bowel‐cleansing rate, defined as Harefield Cleansing Scale grade A or B as evaluated by blinded central readers. Secondary endpoints included the presence of residual air bubbles. Adverse events and laboratory evaluations were monitored to assess safety. Tolerability was assessed via participant interview. Results: Overall, 235 participants were randomized, and 224 were included in the per‐protocol analysis (PBK, 112; OSS, 112). Successful bowel cleansing was achieved for 95.5% (107/112) in the PBK group, which was non‐inferior to the OSS group (98.2%, 110/112) with a difference of −2.7% (one sided 97.5% confidence limit, −8.1%). The participants in the PBK group had fewer intraluminal bubbles (0.9% vs 81.3%, P < 0.001) and reported a lower incidence of nausea and vomiting, with better acceptance, taste, and willingness to repeat the regimen than those in the OSS group (all P < 0.05). Conclusion: The novel sulfate tablet, PBK‐1701TC, was non‐inferior to OSS with respect to bowel‐cleansing efficacy and exhibited better safety and tolerability in adults undergoing colonoscopy. [ABSTRACT FROM AUTHOR]